(CercleFinance.com) – Barclays announced on Wednesday that it had lowered its target price on the Eurofins Scientific stock, which it reduced from 105 to 100 euros following the stock market underperformance following the publication of the group’s half-year results.
In a research note, the consultancy – which maintains its ‘overweight’ recommendation on the bio-analytical giant – says it has come to the conclusion that concerns surrounding its short-term and long-term profit margins are ‘exaggerated’.
“We expect organic growth to pick up in the second half of the year and believe the investment case remains fundamentally attractive,” he concludes.
Copyright © 2022 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
